Brokerages Set ICU Medical, Inc. (NASDAQ:ICUI) Target Price at $170.25

Shares of ICU Medical, Inc. (NASDAQ:ICUI) have received a consensus rating of “Moderate Buy” from the five research firms that are covering the company, Marketbeat reports. Two equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $170.25.

A number of equities analysts have weighed in on the company. Raymond James upped their price target on ICU Medical from $158.00 to $190.00 and gave the stock an “outperform” rating in a report on Thursday, September 12th. StockNews.com raised shares of ICU Medical from a “hold” rating to a “buy” rating in a report on Thursday, September 12th. KeyCorp boosted their price objective on shares of ICU Medical from $147.00 to $198.00 and gave the stock an “overweight” rating in a report on Tuesday, October 15th. Needham & Company LLC reissued a “hold” rating on shares of ICU Medical in a research report on Thursday, October 10th. Finally, Jefferies Financial Group assumed coverage on ICU Medical in a research report on Monday, October 14th. They set a “hold” rating and a $183.00 target price on the stock.

ICU Medical Trading Up 0.2 %

Shares of ICUI stock opened at $175.44 on Thursday. The company has a quick ratio of 1.08, a current ratio of 2.41 and a debt-to-equity ratio of 0.76. ICU Medical has a fifty-two week low of $78.28 and a fifty-two week high of $188.53. The firm’s 50 day moving average price is $173.70 and its two-hundred day moving average price is $136.46. The stock has a market cap of $4.27 billion, a price-to-earnings ratio of -71.61 and a beta of 0.66.

ICU Medical (NASDAQ:ICUI) last posted its earnings results on Wednesday, August 7th. The medical instruments supplier reported $1.56 earnings per share for the quarter, beating the consensus estimate of $1.00 by $0.56. ICU Medical had a negative net margin of 3.07% and a positive return on equity of 5.01%. The business had revenue of $596.50 million for the quarter, compared to analyst estimates of $556.64 million. During the same quarter in the previous year, the business posted $1.58 EPS. The business’s quarterly revenue was up 8.6% on a year-over-year basis. On average, analysts anticipate that ICU Medical will post 3.81 EPS for the current year.

Insider Buying and Selling

In other news, VP Virginia Ruth Sanzone sold 2,050 shares of the company’s stock in a transaction on Thursday, August 8th. The stock was sold at an average price of $144.11, for a total transaction of $295,425.50. Following the completion of the sale, the vice president now directly owns 4,482 shares of the company’s stock, valued at $645,901.02. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. In related news, VP Virginia Ruth Sanzone sold 2,050 shares of the company’s stock in a transaction that occurred on Thursday, August 8th. The shares were sold at an average price of $144.11, for a total value of $295,425.50. Following the completion of the sale, the vice president now owns 4,482 shares in the company, valued at approximately $645,901.02. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Daniel Woolson sold 2,502 shares of ICU Medical stock in a transaction that occurred on Friday, August 30th. The stock was sold at an average price of $163.22, for a total transaction of $408,376.44. Following the transaction, the vice president now owns 13,107 shares in the company, valued at approximately $2,139,324.54. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 40,552 shares of company stock worth $6,679,322. Corporate insiders own 6.70% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Motco acquired a new position in ICU Medical during the first quarter worth $29,000. Innealta Capital LLC bought a new stake in shares of ICU Medical during the 2nd quarter worth about $32,000. GAMMA Investing LLC increased its holdings in shares of ICU Medical by 75.1% during the 1st quarter. GAMMA Investing LLC now owns 310 shares of the medical instruments supplier’s stock valued at $33,000 after acquiring an additional 133 shares during the last quarter. Hexagon Capital Partners LLC raised its stake in shares of ICU Medical by 162.7% in the 3rd quarter. Hexagon Capital Partners LLC now owns 197 shares of the medical instruments supplier’s stock valued at $36,000 after acquiring an additional 122 shares in the last quarter. Finally, Allworth Financial LP lifted its holdings in ICU Medical by 100.0% in the 3rd quarter. Allworth Financial LP now owns 200 shares of the medical instruments supplier’s stock worth $36,000 after purchasing an additional 100 shares during the last quarter. Institutional investors own 96.10% of the company’s stock.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.